Last reviewed · How we verify
Monoferric
At a glance
| Generic name | Monoferric |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Target | Serotransferrin |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Approved indications
- Iron deficiency anemia
Common side effects
- Hypophosphatemia
- Nausea
- Rash
- Hypersensitivity reactions
- Abdominal pain
- Vomiting
- Constipation
- Diarrhea
- Fatigue
- Pyrexia
- Chest pain
- Chills
Key clinical trials
- Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) (PHASE4)
- Post-operative Intravenous Iron to Treat Iron-deficiency Anemia in Patients Undergoing Cardiac Surgery (PHASE2)
- Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy (PHASE3)
- Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia (PHASE3)
- Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy (PHASE3)
- Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) (PHASE3)
- IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department (PHASE3)
- Monoferric for Prenatal Iron Deficiency (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monoferric CI brief — competitive landscape report
- Monoferric updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI